CLBX — Cellbxhealth Share Price
Last trade - 00:00- £3.87m
- £2.27m
- £2.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.33 | ||
| Price to Tang. Book | 0.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.48 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -110.29% | ||
| Return on Equity | -87.18% | ||
| Operating Margin | -627.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.76 | 1.01 | 1.04 | 2.19 | 2.86 | 3.05 | 3.98 | 33.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cellbxhealth PLC, formerly ANGLE plc, is a global precision circulating tumor cell (CTC) intelligence company specializing in innovative circulating tumor cell solutions for use in research, drug development and clinical oncology. The product portfolio comprises the Parsortix platform with associated consumables and assays. Its Parsortix platform harvests CTCs from blood and enables comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows - supporting research, drug development and clinical oncology. Its Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis.Its Parsortix PR1 System is a semi-automated platform for epitope-independent CTC isolation, used in research and clinical trials for multiple cancer types.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- December 4th, 2003
- Public Since
- March 17th, 2004
- No. of Employees
- 119
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 322,641,668
- Address
- The Surrey Research Park, 10 Nugent Road, GUILDFORD, GU2 7AF
- Web
- https://www.angleplc.com/
- Phone
- +44 1483343434
- Auditors
- PricewaterhouseCoopers LLP
Latest News for CLBX
Upcoming Events for CLBX
Similar to CLBX
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Aoti
London Stock Exchange
Aptamer
London Stock Exchange
Cambridge Nutritional Sciences
London Stock Exchange
FAQ
As of Today at 18:51 UTC, shares in Cellbxhealth are trading at 1.20p. This share price information is delayed by 15 minutes.
Shares in Cellbxhealth last closed at 1.20p and the price had moved by -88.57% over the past 365 days. In terms of relative price strength the Cellbxhealth share price has underperformed the FTSE All Share Index by -90.03% over the past year.
The overall consensus recommendation for Cellbxhealth is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCellbxhealth does not currently pay a dividend.
Cellbxhealth does not currently pay a dividend.
Cellbxhealth does not currently pay a dividend.
To buy shares in Cellbxhealth you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1.20p, shares in Cellbxhealth had a market capitalisation of £3.87m.
Here are the trading details for Cellbxhealth:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: CLBX
Based on an overall assessment of its quality, value and momentum Cellbxhealth is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cellbxhealth is 17.00p. That is 1316.67% above the last closing price of 1.20p.
Analysts covering Cellbxhealth currently have a consensus Earnings Per Share (EPS) forecast of -£0.04 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cellbxhealth. Over the past six months, its share price has underperformed the FTSE All Share Index by -84.67%.
As of the last closing price of 1.20p, shares in Cellbxhealth were trading -79.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cellbxhealth PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 1.20p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cellbxhealth's management team is headed by:
- Garth Selvey - NEC
- Andrew Newland - CEO
- Ian Griffiths - FID
- Jan Groen - NID
- Brian Howlett - NID